| |
|
| |
| THE GENERAL ASSEMBLY OF PENNSYLVANIA |
| |
| SENATE BILL |
|
| |
| |
| INTRODUCED BY BOSCOLA, BROWNE, WILLIAMS, ORIE, TARTAGLIONE, STOUT, FONTANA, HUGHES AND COSTA, APRIL 6, 2009 |
| |
| |
| REFERRED TO JUDICIARY, APRIL 6, 2009 |
| |
| |
| |
| AN ACT |
| |
1 | Amending the act of April 14, 1972 (P.L.233, No.64), entitled |
2 | "An act relating to the manufacture, sale and possession of |
3 | controlled substances, other drugs, devices and cosmetics; |
4 | conferring powers on the courts and the secretary and |
5 | Department of Health, and a newly created Pennsylvania Drug, |
6 | Device and Cosmetic Board; establishing schedules of |
7 | controlled substances; providing penalties; requiring |
8 | registration of persons engaged in the drug trade and for the |
9 | revocation or suspension of certain licenses and |
10 | registrations; and repealing an act," further providing for |
11 | Schedule I controlled substances. |
12 | The General Assembly of the Commonwealth of Pennsylvania |
13 | hereby enacts as follows: |
14 | Section 1. Section 4(1) of the act of April 14, 1972 |
15 | (P.L.233, No.64), known as The Controlled Substance, Drug, |
16 | Device and Cosmetic Act, amended November 24, 1999 (P.L.894, |
17 | No.55), is amended to read: |
18 | Section 4. Schedules of Controlled Substances.--The |
19 | following schedules include the controlled substances listed or |
20 | to be listed by whatever official name, common or usual name, |
21 | chemical name, or trade name designated. |
22 | (1) Schedule I--In determining that a substance comes within |
|
1 | this schedule, the secretary shall find: a high potential for |
2 | abuse, no currently accepted medical use in the United States, |
3 | and a lack of accepted safety for use under medical supervision. |
4 | The following controlled substances are included in this |
5 | schedule: |
6 | (i) Any of the following opiates, including their isomers, |
7 | esters, ethers, salts, and salts of isomers, esters, and ethers, |
8 | unless specifically excepted, whenever the existence of such |
9 | isomers, esters, ethers and salts is possible within the |
10 | specific chemical designation: |
11 | 1. Acetylmethadol. |
12 | 2. Allylprodine. |
13 | 3. Alphacetylmethadol. |
14 | 4. Alphameprodine. |
15 | 5. Alphamethadol. |
16 | 6. Benzethidine. |
17 | 7. Betacetylmethadol. |
18 | 8. Betameprodine. |
19 | 9. Betamethadol. |
20 | 10. Betaprodine. |
21 | 11. Clonitazene. |
22 | 12. Dextromoramide. |
23 | 13. Dextrorphan (except its methylether). |
24 | 14. Diampromide. |
25 | 15. Diethylthiambutene. |
26 | 16. Dimenoxadol. |
27 | 17. Dimepheptanol. |
28 | 18. Dimethylthiambutene. |
29 | 19. Dioxaphetyl butyrate. |
30 | 20. Dipipanone. |
|
1 | 21. Ethylmethylthiambutene. |
2 | 22. Etonitazene. |
3 | 23. Etoxeridine. |
4 | 24. Furethidine. |
5 | 25. Hydroxypethidine. |
6 | 26. Ketobemidone. |
7 | 27. Levomoramide. |
8 | 28. Levophenacylmorphan. |
9 | 29. Morpheridine. |
10 | 30. Noracymethadol. |
11 | 31. Norlevorphanol. |
12 | 32. Normethadone. |
13 | 33. Norpipanone. |
14 | 34. Phenadoxone. |
15 | 35. Phenampromide. |
16 | 36. Phenomorphan. |
17 | 37. Phenoperidine. |
18 | 38. Piritramide. |
19 | 39. Proheptazine. |
20 | 40. Properidine. |
21 | 41. Racemoramide. |
22 | 42. Trimeperidine. |
23 | (ii) Any of the following opium derivatives, their salts, |
24 | isomers and salts of isomers, unless specifically excepted, |
25 | whenever the existence of such salts, isomers and salts of |
26 | isomers is possible within the specific chemical designation: |
27 | 1. Acetorphine. |
28 | 2. Acetyldihydrocodeine. |
29 | 3. Benzylmorphine. |
30 | 4. Codeine methylbromide. |
|
1 | 5. Codeine-N-Oxide. |
2 | 6. Cyprenorphine. |
3 | 7. Desomorphine. |
4 | 8. Dihydromorphine. |
5 | 9. Etorphine. |
6 | 10. Heroin. |
7 | 11. Hydromorphinol. |
8 | 12. Methyldesorphine. |
9 | 13. Methylhydromorphine. |
10 | 14. Morphine methylbromide. |
11 | 15. Morphine methylsulfonate. |
12 | 16. Morphine-N-Oxide. |
13 | 17. Myrophine. |
14 | 18. Nicocodeine. |
15 | 19. Nicomorphine. |
16 | 20. Normorphine. |
17 | 21. Pholcodine. |
18 | 22. Thebacon. |
19 | (iii) Any material, compound, mixture, or preparation which |
20 | contains any quantity of the following hallucinogenic |
21 | substances, their salts, isomers, and salts of isomers, unless |
22 | specifically excepted, whenever the existence of such salts, |
23 | isomers, and salts of isomers is possible within the specific |
24 | chemical designation: |
25 | 1. 3,4-methylenedioxy amphetamine. |
26 | 2. 5-methoxy-3,4-methylenedioxy amphetamine. |
27 | 3. 3,4,5-trimethoxy amphetamine. |
28 | 4. Bufotenine. |
29 | 5. Diethyltryptamine. |
30 | 6. Dimethyltryptamine. |
|
1 | 7. 4-methyl-2,5-dimethoxyamphetamine. |
2 | 8. Ibogaine. |
3 | 9. Lysergic acid diethylamide. |
4 | 10. Mescaline. |
5 | 11. Peyote. |
6 | 12. N-ethyl-3-piperidyl benzilate. |
7 | 13. N-methyl-3-piperidyl benzilate. |
8 | 14. Psilocybin. |
9 | 15. Psilocyn. |
10 | 16. Tetrahydrocannabinols. |
11 | 17. Salvia Divinorum. |
12 | (iv) Marihuana. |
13 | (v) Any material, compound, mixture or preparation which |
14 | contains any quantity of the following substances, including the |
15 | salts, isomers and salts of isomers: |
16 | 1. Methaqualone. |
17 | (vi) Gamma hydroxybutyric acid, any salt, hydroxybutyric |
18 | compound, derivative or preparation of gamma hydroxybutyric |
19 | acid, including any isomers, esters and ethers and salts of |
20 | isomers, esters and ethers of gamma hydroxybutyric acid, except |
21 | gamma-butyrolactone (GBL), whenever the existence of such |
22 | isomers, esters and salts is possible within the specific |
23 | chemical designation. For purposes of security requirements |
24 | imposed by law or regulation upon registered distributors and |
25 | registered manufacturers, this substance when manufactured, |
26 | distributed or possessed in accordance with an exemption |
27 | approved under section 505(i) of the Federal Food, Drug, and |
28 | Cosmetic Act (52 Stat. 1040, 21 U.S.C. § 301 et seq.) shall, |
29 | notwithstanding any other provision of this act, be classified |
30 | as a controlled substance in Schedule III of this section. |
|
1 | * * * |
2 | Section 2. This act shall take effect in 60 days. |
|